The immune system constantly patrols the body for abnormal cells, including cancer cells. Among its most powerful weapons are CD8-positive cytotoxic T cells, which recognize tumor-associated signals and can directly destroy malignant cells. Gastric tumors, however, often create an immunosuppressive environment that prevents these lymphocytes from functioning properly. Immune checkpoint inhibitors, or ICIs, are designed to release some of the molecular brakes placed on T cells, but their success depends heavily on the signals already operating inside the tumor.

D-serine belongs to a group of molecules known as D-amino acids. Most amino acids used to build proteins in humans are L-amino acids, while D-amino acids are their mirror-image forms, or enantiomers. Although D-amino acids were once considered biologically insignificant, scientists now know that they can occur naturally in body fluids and may originate from food, intestinal microbes, or cellular metabolism. D-serine is already recognized for its role in nervous-system signaling, but the Keio team investigated whether it could also influence cancer immunity.

The researchers used mouse models of gastric cancer and introduced different D-amino acids and their corresponding L-amino acids into tumors. Among the compounds tested, only D-serine produced a clear increase in tumor growth compared with untreated controls. Detailed analysis showed that the molecule was not simply feeding the cancer cells. Instead, it altered the immune ecosystem surrounding the tumors, increasing the abundance and activity of anti-inflammatory immune cells, especially M2-like macrophages.

Macrophages are highly adaptable immune cells that can either attack tumors or support their growth, depending on the chemical signals around them. In the D-serine-treated tumors, macrophages acquired a tumor-promoting, immunosuppressive profile. At the same time, the number of CD8-positive cytotoxic T cells fell, and the T cells that remained showed markedly reduced activity. This combination—more suppressive macrophages and fewer functional killer T cells—created conditions that allowed gastric tumors to expand with less immune resistance.

The team then examined the molecular secretions of tumor-associated macrophages, commonly called TAMs. In tumors exposed to D-serine, these cells released unusually high amounts of fibronectin 1, or FN1, and secreted phosphoprotein 1, known as SPP1 or osteopontin. Both molecules have been associated with immune regulation and tumor progression. In this setting, they appeared to contribute to the suppression of CD8-positive T cells, helping the tumor maintain an immune-protected niche.

One experiment provided evidence that SPP1 was an important part of this pathway. When the researchers administered antibodies designed to neutralize SPP1 in D-serine-enhanced tumors, tumor growth slowed and approached the rate observed in mice with lower D-serine activity. The result suggests that D-serine may operate upstream of a signaling cascade in which macrophages release SPP1 and FN1, ultimately weakening the T-cell response. However, the findings do not yet establish that blocking SPP1 or D-serine will be effective as a treatment in people.

To investigate whether the mouse findings might have clinical relevance, the researchers analyzed patient data from several human cohorts. Patients with gastric cancer had higher serum D-serine concentrations than healthy controls. The highest levels were detected in people with stage IV disease whose tumors had resisted ICI treatment. This association raises the possibility that a blood test for D-serine could help identify patients whose tumors are more likely to evade immunotherapy, although larger prospective studies will be needed before such testing can guide clinical decisions.

The findings are particularly significant because ICIs are increasingly used as first-line treatment for advanced gastric cancer, yet responses vary widely and treatment can cause immune-related adverse events. Measuring D-serine in blood, and potentially in stool, could offer a way to assess the tumor’s immunological state before therapy begins. The researchers are now examining whether D-serine levels can predict treatment response and whether intestinal bacteria responsible for producing the molecule contribute to its accumulation. If future studies confirm the mechanism, therapies aimed at reducing D-serine or interrupting its downstream signals could provide a new strategy for restoring anti-tumor immunity. For now, the work identifies D-serine as a promising biomarker and a potential immune-regulatory target, but its therapeutic value remains to be tested in human clinical trials.

Subject of Research: Animals

Article Title: D-serine as a metabolic immune checkpoint in the tumour microenvironment

News Publication Date: 31-Jul-2026

Web References: https://doi.org/10.1016/j.ebiom.2026.106402; https://www.keio-sujino-lab.com/; https://researchmap.jp/tsujino

References: https://doi.org/10.1016/j.ebiom.2026.106402

Image Credits: Shohei Suzuki and Tomohisa Sujino, Keio University, Japan

Keywords: D-serine, gastric cancer, tumor immunity, immune checkpoint inhibitors, immunotherapy resistance, tumor-associated macrophages, CD8-positive T cells, SPP1, FN1, metabolic immune checkpoint

HTLV-1 is a retrovirus linked to the development of adult T-cell leukemia/lymphoma (ATL), a malignancy characterized by aggressive clinical progression and poor prognosis. Despite infection being widespread in certain endemic regions, including parts of southwestern Japan, the majority of infected individuals remain asymptomatic for life. The virus’s ability to persist in a quiescent form inside host cells is a major factor underlying its evasion of immune clearance and its latent oncogenic potential. Until now, the molecular underpinnings responsible for this dormancy remained elusive.

The team at Kumamoto University, led by Professor Yorifumi Satou, determined that an intragenic region within the HTLV-1 genome serves as a viral silencer. This sequence recruits the host’s transcriptional regulation machinery, centering on the RUNX family of transcription factors, particularly RUNX1. By recruiting RUNX1 complexes, this viral element suppresses the transcriptional activity of HTLV-1 genes, silencing viral gene expression and therefore curbing active virus production. This stealth strategy ensures the virus remains undetected by the host immune system, securing long-term persistence within infected T-cells.

Through a series of meticulous experimental studies, the researchers demonstrated that genetic disruption or deletion of this viral silencer results in heightened viral transcriptional activation. This increased expression translates into greater immune visibility and accelerated clearance of infected cells in vitro. These findings confirm that the silencer acts as a crucial molecular brake to maintain HTLV-1 in a low-profile latent state. The ability to switch off viral gene expression using host transcription factors represents a finely tuned evolutionary adaptation unique to HTLV-1’s survival strategy.

Intriguingly, the team extended their analysis to the human immunodeficiency virus type 1 (HIV-1), another retrovirus with a contrasting survival tactic marked by active replication and immune system evasion through rapid mutation rather than latency. When the identified HTLV-1 silencer element was artificially inserted into the HIV-1 genome, the virus adopted a more latent phenotype. HIV-1 replication and cytopathic effects on host cells were significantly reduced, mimicking the dormancy that HTLV-1 exploits. This cross-viral functional integration hints at the broader applicability of silencer-based gene regulation among retroviruses and suggests potential novel therapeutic strategies for HIV-1 by inducing or enhancing latency.

The recruitment of the RUNX transcription complex is central to this silencing mechanism. RUNX1 is a well-studied transcription factor involved in hematopoiesis and immune regulation. By leveraging an essential host transcriptional regulator, HTLV-1 tightly controls its gene expression, preventing the activation of immune-inflammatory pathways that could lead to infected cell elimination. This research highlights how retroviruses can co-opt host factors not only for replication but also for immune evasion, reflecting an intricate virus-host co-evolutionary relationship.

Professor Satou emphasized the elegance of this viral adaptation: “HTLV-1’s intragenic silencer acts as a molecular cloak, enabling the virus to dwell silently within the host’s immune landscape. Understanding this natural invisibility cloak provides a vital blueprint for developing targeted therapies that disrupt viral latency and enhance immune-mediated clearance.” The potential for therapeutically modulating this silencer or its interactions with RUNX complexes could transform treatment strategies for HTLV-1 infections and associated malignancies.

This study also sheds light on the broader biological significance of latency in retroviral pathogenesis. Latency is a double-edged sword that allows persistent infection but complicates eradication efforts. By dissecting the molecular circuitry behind HTLV-1’s latent state, the research community gains critical insight that may inform cure strategies not only for HTLV-1 but potentially other retroviral infections and latent viral reservoirs in human diseases.

Another remarkable aspect is the contextual specificity of this silencer within the HTLV-1 genome. The intragenic nature of the silencing element distinguishes it from classical promoter or enhancer regions, revealing a layered complexity in viral gene regulation. This intragenic silencer forms part of the virus’s regulatory architecture that balances between gene activation necessary for viral transmission and the dormancy needed for survival within the host environment.

The implications of this discovery extend into epidemiology and public health, particularly for endemic areas where HTLV-1 infection rates are highest. Targeted interventions disrupting viral latency may enable earlier detection, treatment, and potential prevention of ATL progression. Furthermore, understanding how to manipulate viral silencing holds promise for reducing viral loads and associated inflammation, potentially improving patient outcomes.

The research methodology combined molecular genetics, virology, and immunology, leveraging human tissue samples and advanced transcriptional analysis techniques. These comprehensive experimental approaches ensured that the findings reflect biologically relevant mechanisms operational in vivo, dramatically strengthening the translational potential of the insights gained.

In summary, this landmark research illuminates a fundamental mechanism by which HTLV-1 orchestrates its stealth existence through an intragenic viral silencer element recruiting the RUNX transcription factor complex. By suppressing viral gene expression, HTLV-1 achieves immune invisibility, persistence, and latency, thereby contributing to its oncogenic potential. The discovery that this silencer can impose a similar latent phenotype on HIV-1 broadens the therapeutic horizon, suggesting new avenues in retroviral disease management aiming to control viral replication and latency.

As the scientific community continues to grapple with chronic viral infections, findings such as these underscore the critical importance of understanding viral gene regulation at a granular level. The capacity to intentionally toggle viral latency mechanisms could revolutionize antiviral therapies and immunomodulatory approaches, offering renewed hope to millions affected by persistent retroviral diseases worldwide.

Subject of Research: Human tissue samples

Article Title: Intragenic viral silencer element regulates HTLV-1 latency via RUNX complex recruitment

News Publication Date: 13-May-2025

Web References: http://dx.doi.org/10.1038/s41564-025-02006-7

Image Credits: Yorifumi Satou, Kumamoto University

Keywords: Retroviruses, Leukemia, Cancer, Human immunodeficiency virus, Viruses